Screener
Ionis Pharmaceuticals IONS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Ionis Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
FAQ
- What is Ionis Pharmaceuticals's EBITDA margin?
- Ionis Pharmaceuticals (IONS) reported EBITDA margin of -66.3% in Q2 2026.
- How has Ionis Pharmaceuticals's EBITDA margin changed year-over-year?
- Ionis Pharmaceuticals's EBITDA margin decreased by 145.3% year-over-year, from -27% to -66.3%.
- What is the long-term trend for Ionis Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's EBITDA margin has grown at a 12.7% compound annual growth rate (CAGR), from -21.5% to -39.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Ionis Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude